Efficacy and safety of avelumab + axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial.

B Venugopal, Toni K. Choueiri, Konstantin Penkov et al.|Journal of Clinical Oncology|2026

Cited by 0